Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

SS Innovations wows at SMRSC 2026 conference

SS Innovations used its SMRSC 2026 conference in New Delhi to showcase a wider set of robotic concepts and to underscore a sharp rise in event scale and clinical activity versus last year.

Attendance at the three-day conference climbed to more than 1,600 in-person attendees and 1,800 virtual participants from 19 nations, topping last year’s turnout. The company also expanded the live clinical program, with physicians performing 10 live telesurgeries and 13 live robotic surgeries across multiple specialties using its SSI Mantra system.

The biggest technology reveal was the SSI Vimana Aero, a drone-deployed surgical robotic system designed for battlefield use. The platform is being developed to land near a casualty, deploy two miniature robotic arms with seven degrees of freedom, and allow a trauma surgeon to operate remotely through an SSI Mantra surgeon command center. The company says the system is being designed for procedures including hemorrhage control, wound repair, chest decompression, shrapnel extraction and field suturing.

SS Innovations also introduced the SSI Avtara, a humanoid surgical platform under conceptual development, and the SSI Operion, a mobile operating room built on a wheeled chassis with overhead-integrated robotics. In addition, the company highlighted new single-arm robotic endoscopy and ultrasound assist carts that are in early clinical validation in India.

The conference featured dozens of panel discussions across urology, thoracic, gastroenterology, head and neck, gynecology, colorectal, general, pediatric and cardiac specialties. Among the notable participants were Dr. Fred Moll, Shri Pratap Rao Jadhav, Sri Madhusudan Sai and Dr. Mylswamy Annadurai. As a result of these announcements, the company's shares have moved 1.44% on the market, and are now trading at a price of $4.93. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS